

IRADIMED CORP  
Form 8-K/A  
November 03, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, DC 20549

**FORM 8-K/A**

**CURRENT REPORT PURSUANT**  
**TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **July 21, 2017**

**IRADIMED CORPORATION**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**001-36534**  
(Commission File Number)

**1025 Willa Springs Dr., Winter Springs, FL**  
(Address of Principal Executive Offices)

**73-1408526**  
(IRS Employer Identification No.)

**32708**  
(Zip Code)

**(407) 677-8022**

Edgar Filing: IRADIMED CORP - Form 8-K/A

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Explanatory Note**

This Amendment No. 1 to the Current Report on Form 8-K amends Item 1.01 of the Current Report on Form 8-K filed on July 21, 2017 (the Original Form 8-K ) solely to correct an error on page 1 of the Walters-Hoffert Amendment set forth on Exhibit 10.3 to the Original Form 8-K. As previously filed, the preamble of the Walters-Hoffert Amendment reflected incorrectly that Roth Capital Partners, LLC was the registered holder of the Warrant, which has been corrected on Exhibit 10.1 to this Amendment No. 1. No other changes have been made to the Original Form 8-K.

**Item 1.01 Entry Into a Material Definitive Agreement.**

The Exhibit 10.1 attached hereto is a replacement of Exhibit 10.3 of the Original Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

10.1 Walters-Hoffert Amendment

**EXHIBIT INDEX**

| <b>Exhibit<br/>No.</b> |                                  | <b>Document</b> |
|------------------------|----------------------------------|-----------------|
| 10.1                   | <u>Walters-Hoffert Amendment</u> |                 |

3

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**IRADIMED CORPORATION**

Date: November 3, 2017

|        |                         |
|--------|-------------------------|
| By:    | /s/ Chris Scott         |
| Name:  | Chris Scott             |
| Title: | Chief Financial Officer |